← Leaderboards
Michael Ilya Bukrinsky
Picower Institute For Medical Research
$28,728,086
Attributed
$41,013,624
Total exposure
31
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,013,624 · 31
By mechanism
R01$22,190,234 · 11
P30$12,381,450 · 4
R21$5,381,890 · 13
R56$782,500 · 1
R03$277,550 · 2
Top collaborators
- Dmitri Sviridov27 shared
- Michael Leo Fitzgerald12 shared
- William R Tyor6 shared
- Amol Anant Kulkarni5 shared
- Grigori N Enikolopov4 shared
- Janet Lo4 shared
- Stephanie L Constant2 shared
- Alexei Koulakov2 shared
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsInnovationAffectMediatingCellsHiv-1PathogenesisMacrophageBaseImpairmentInfectionCholesterol HomeostasisPharmaceutical PreparationsPreventProgramsAtherosclerosisStructurePlayVirusResearch PersonnelMetabolicIn VivoNef ProteinProteins
Grant awards (100)
The effects of cART and HIV-1 infection on neural circuitry$733,568
R01 · FY2025 · MH
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$672,761
R01 · FY2025 · NS · contact PI
Developmental Core$339,623
P30 · FY2025 · AI · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation in cocaine use.$196,876
R21 · FY2025 · DA
The effects of cART and HIV-1 infection on neural circuitry$856,064
R01 · FY2024 · MH
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$744,154
R01 · FY2024 · NS · contact PI
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$627,036
R01 · FY2024 · HL · contact PI
Epigenetic mechanisms of HAND pathogenesis$382,072
R21 · FY2024 · NS · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation in cocaine use.$263,119
R21 · FY2024 · DA
Developmental Core$257,526
P30 · FY2024 · AI · contact PI
Developmental Core$872,961
P30 · FY2023 · AI · contact PI
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$762,862
R01 · FY2023 · NS · contact PI
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$634,030
R01 · FY2023 · HL · contact PI
Trained immunity induced by Nef-containing extracellular vesicles$201,875
R21 · FY2023 · AI · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation$156,884
R21 · FY2023 · NS · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation$79,242
R21 · FY2023 · NS
Supplement to R01 NS124477$34,154
R01 · FY2023 · NS · contact PI
Developmental Core$1,453,999
P30 · FY2022 · AI · contact PI
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$680,858
R01 · FY2022 · NS · contact PI
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$640,876
R01 · FY2022 · HL · contact PI
Trained immunity induced by Nef-containing extracellular vesicles$242,250
R21 · FY2022 · AI · contact PI
Development of NLRP3 inhibitors for HIV-associated neuroinflammation$212,000
R21 · FY2022 · NS
Developmental Core$4,557,548
P30 · FY2021 · AI · contact PI
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$777,389
R01 · FY2021 · HL · contact PI
Novel pathogenic mechanism of HIV-associated CNS neurological disorders$730,589
R01 · FY2021 · NS · contact PI
Lipid raft therapy â a novel therapeutic approach for HIV-associated cardiometabolic co-morbidities$693,497
R01 · FY2021 · HL · contact PI
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$784,578
R01 · FY2020 · HL · contact PI
Developmental Core$274,606
P30 · FY2020 · AI · contact PI
Alterations in Neuronal Networks induced by cART and HIV$188,271
R21 · FY2020 · MH
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$793,579
R01 · FY2019 · HL · contact PI
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$382,352
R01 · FY2019 · HL · contact PI
Core B: Developmental Core$336,610
P30 · FY2019 · AI · contact PI
Alterations in Neuronal Networks induced by cART and HIV$241,370
R21 · FY2019 · MH
Nef and neuroAIDS: role of cholesterol metabolism impairment and inflammation$200,000
R01 · FY2019 · NS · contact PI
Epigenetic Reprogramming in HIV-Associated Cardio-Vascular Disease$787,681
R01 · FY2018 · HL · contact PI
Core B: Developmental Core$516,094
P30 · FY2018 · AI · contact PI
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$390,491
R01 · FY2018 · HL · contact PI
Nef and neuroAIDS: role of cholesterol metabolism impairment and inflammation$200,000
R01 · FY2018 · NS · contact PI
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$398,415
R01 · FY2017 · HL · contact PI
Core B: Developmental Core$374,081
P30 · FY2017 · AI · contact PI
Nef and neuroAIDS: role of cholesterol metabolism impairment and inflammation$200,000
R01 · FY2017 · NS · contact PI
Structural characterization of the Nef-calnexin complex$191,875
R21 · FY2017 · AI · contact PI
Metabolic complications of HIV disease caused by Nef released from HIV-infected cells$420,750
R01 · FY2016 · HL · contact PI
Core B: Developmental Core$411,695
P30 · FY2016 · AI · contact PI
Structural characterization of the Nef-calnexin complex$243,808
R21 · FY2016 · AI · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$728,214
R01 · FY2015 · HL · contact PI
Core B: Developmental Core$323,066
P30 · FY2015 · AI · contact PI
HIV-1 Nef regulates activity of the ER chaperone calnexin$209,602
R21 · FY2015 · AI · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$727,875
R01 · FY2014 · HL · contact PI
HIV-1 Nef regulates activity of the ER chaperone calnexin$221,900
R21 · FY2014 · AI · contact PI
Developmental$51,427
P30 · FY2014 · AI · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$677,773
R01 · FY2013 · HL · contact PI
Mechanisms of virus-induced impairment of reverse cholesterol transport$306,327
R01 · FY2013 · HL · contact PI
Developmental$82,084
P30 · FY2013 · AI · contact PI
Developmental$1,968,139
P30 · FY2012 · AI · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$716,126
R01 · FY2012 · HL · contact PI
Mechanisms of virus-induced impairment of reverse cholesterol transport$323,796
R01 · FY2012 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$156,292
R01 · FY2012 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$124,801
R01 · FY2012 · HL · contact PI
Developmental$455,005
P30 · FY2011 · AI · contact PI
Mechanisms of virus-induced impairment of reverse cholesterol transport$325,761
R01 · FY2011 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$124,801
R01 · FY2011 · HL · contact PI
HIV Disease and Impairement of High Density Lipoprotein Metabolism$748,717
R01 · FY2010 · HL · contact PI
Cyclophilin-CD147 interaction in autoimmune arthritis$391,250
R56 · FY2010 · AI · contact PI
Mechanisms of virus-induced impairment of reverse cholesterol transport$324,914
R01 · FY2010 · HL · contact PI
Targeting HIV infectivity by stimulating cholesterol efflux$191,357
R21 · FY2010 · AI · contact PI
Developmental$106,986
P30 · FY2010 · AI · contact PI
Targeting HIV infectivity by stimulating cholesterol efflux$9,565
R21 · FY2010 · AI · contact PI
Cyclophilin-CD147 interaction in autoimmune arthritis$391,250
R56 · FY2009 · AI · contact PI
Mechanisms of virus-induced impairment of reverse cholesterol transport$340,970
R01 · FY2009 · HL · contact PI
Contribution of cyclophilins to leukocyte recruitment in lung inflammation$327,916
R01 · FY2009 · AI · contact PI
Targeting HIV infectivity by stimulating cholesterol efflux$234,500
R21 · FY2009 · AI · contact PI
Oxadaizols: Rationally designed compounds targeting HIV nuclear importation$227,646
R21 · FY2008 · AI · contact PI
Oxadaizols: Rationally designed compounds targeting HIV nuclear importation$192,869
R21 · FY2007 · AI · contact PI
The Role of Vpr in HIV-1 Nuclear Translocation$344,458
R01 · FY2006 · AI · contact PI
HIV Impairs Reverse Cholesterol Transport$188,137
R21 · FY2006 · DK · contact PI
HIV Impairs Reverse Cholesterol Transport$9,007
R21 · FY2006 · DK · contact PI
The Role of Vpr in HIV-1 Nuclear Translocation$382,621
R01 · FY2005 · AI
Leukocyte recruitment by cyclophilinc-CD147 interaction$229,500
R21 · FY2005 · AI
HIV Impairs Reverse Cholesterol Transport$205,915
R21 · FY2005 · DK
HIV infection and reverse cholesterol transport$40,320
R03 · FY2005 · TW
The Role of Vpr in HIV-1 Nuclear Translocation$440,657
R01 · FY2004 · AI
NUCLEAR TRANSLOCATION OF HIV 1 GENOME AS A DRUG TARGET$266,000
R01 · FY2004 · AI
Leukocyte recruitment by cyclophilin-CD147 interaction$191,250
R21 · FY2004 · AI
CD4+ memory T cell recruitment by cyclophilin$76,000
R03 · FY2004 · AI
HIV infection and reverse cholesterol transport$40,320
R03 · FY2004 · TW
CD4+ memory T cell recruitment by cyclophilin$4,590
R03 · FY2004 · AI
The Role of Vpr in HIV-1 Nuclear Translocation$355,060
R01 · FY2003 · AI
NUCLEAR TRANSLOCATION OF HIV 1 GENOME AS A DRUG TARGET$266,000
R01 · FY2003 · AI
Imaging Technology for HIV Nuclear Import Inhibitors$228,000
R21 · FY2003 · AI
The Role of Vpr in HIV-1 Nuclear Translocation$79,049
R01 · FY2003 · AI
CD4+ memory T cell recruitment by cyclophilin$76,000
R03 · FY2003 · AI
HIV infection and reverse cholesterol transport$40,320
R03 · FY2003 · TW
NUCLEAR TRANSLOCATION OF HIV 1 GENOME AS A DRUG TARGET$266,000
R01 · FY2002 · AI
Imaging Technology for HIV Nuclear Import Inhibitors$228,000
R21 · FY2002 · AI
The Role of Vpr in HIV-1 Nuclear Translocation$178,786
R01 · FY2002 · AI
Role of Vpr in HIV-1 Nuclear Translocation$215,000
R21 · FY2001 · AI
NUCLEAR TRANSLOCATION OF HIV 1 GENOME AS A DRUG TARGET$176,198
R01 · FY2001 · AI
NUCLEAR TRANSLOCATION OF HIV 1 GENOME AS A DRUG TARGET$115,411
R01 · FY2001 · AI
VPR AND HIV1 NUCLEAR TRANSLOCATION$220,027
R01 · FY2000 · AI